The Swedish National Register for systemic treatment of Psoriasis (PsoReg)
Registry category: Skin diseases and sexually transmitted diseases
Certification level: 2
Central personal data controller (CPUA): Region Västerbotten
Psoriasis is a systemic disease with inflammation of the skin, and in a third of the patients also the joints. Moderate to severe psoriasis is associated with increased risk of metalbolic syndrome and cardiovascular disease.
Psoriasis is a common disease that affecting 2 - 4 percent of the population. The care of patients with moderate to severe psoriasis often requires systemic treatment with potent drugs.
Psoriasis causes an impact on quality of life comparable to asthma and insulin-treated diabetes.
PsoReg’s purpose is:
- Measuring the effect of systemic tratments as well as compliance with treatment guidelines, such as treatment targets PASI <3 and DLQI ≤ 5.
- Pay attention to comorbidities and the impact of lifestyle on psoriasis and the effect of treatment.
- Contribute to quality enhancement through comparisons between the clinics' way of treating patients.
- Return knowledge gains to both care-givers and patients, and thereby continuously improve psoriasis care with a focus on patient safety, treatment outcomes and equality.
Find contact information on the registry’s website.